# Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

> **NCT01317966** · — · WITHDRAWN · sponsor: **Ming Hou**

## Conditions studied

- Purpura, Thrombocytopenic, Idiopathic

## Interventions

- **DRUG:** rhIL-11

## Key facts

- **NCT ID:** NCT01317966
- **Lead sponsor:** Ming Hou
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2011-12
- **Final completion:** 2012-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No eligible patients were enrolled.
- **Last updated:** 2016-04-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01317966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01317966, "Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01317966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*